Ocugen’s $115 Million Convertible Bet Raises the Stakes for a Trio of Gene Therapy Trials

Ocugen's Q1 net loss hit $19.2M, but a $115M convertible note raise funds three gene therapy programs, including a pivotal Phase 3 for retinitis pigmentosa.

The math at Ocugen is getting harder to ignore. The biotech’s net loss widened to $19.2 million in the first quarter of 2026, up from $15.4 million a year earlier, as operating expenses climbed 21% to $19.4 million. Yet the company is simultaneously betting bigger than ever — raising $115 million through a private placement of convertible notes at 6.75%, due in 2034, with an option to add another $15 million.

That kind of debt doesn’t come cheap. For existing shareholders, the convertible structure carries the double-edged risk of dilution and a heavier interest burden. The market’s response was swift: the stock shed more than 19% on the quarterly release, extending a month-long slide that had already erased 16% of its value. At around €1.24, the shares have slipped below their 200-day moving average.

Management, however, sees the financing as a lifeline, not a liability. After accounting for the conversion of existing high-interest debt, net proceeds from the placement are expected to reach roughly $99.5 million. That, combined with cash reserves of $32.2 million as of March 31 — up from $18.9 million a year earlier — gives the company enough runway to fund operations into 2028. Annual cash burn is estimated between $50 million and $60 million.

The urgency behind the capital raise is clear: Ocugen is running three gene therapy programs in parallel, each approaching a critical inflection point. The lead candidate, OCU400 for retinitis pigmentosa, has fully enrolled its Phase 3 study with 140 patients. Three-year data showed that 88% of treated subjects either improved or maintained their visual function, with no serious treatment-related adverse events. The company plans to begin a rolling biologics license application (BLA) submission in the third quarter of 2026, with completion targeted by mid-2027 and potential FDA approval in the fourth quarter of 2027.

The second program, OCU410ST for Stargardt disease — a condition with no approved therapy in the U.S. or Europe — wrapped up patient enrollment in under nine months. An interim readout is expected in the third quarter of 2026. That data point will be pivotal: it will determine whether the current sample size is sufficient or whether the study needs to be expanded.

The third candidate, OCU410 for geographic atrophy, is set to begin a Phase 3 trial in the third quarter of 2026, enrolling 300 patients across the U.S., EU, and Canada. A Phase 2 study recently demonstrated a 31% reduction in lesion growth, providing the foundation for the larger trial.

Research and development spending rose 18% to $11.3 million in the quarter, while general and administrative costs jumped nearly 26% to $8.1 million. The company attributes the increase to accelerated timelines for its two gene therapy programs and expects expenses to taper once patient recruitment is complete.

Despite the near-term stock pressure, the longer-term picture tells a different story. Ocugen’s shares have gained 112% over the past year, reflecting the market’s willingness to reward pipeline progress — even as it punishes the cost of achieving it. The net loss per share of $0.06 narrowly missed analyst expectations, adding to the bearish sentiment.

What comes next is a test of execution. The convertible note removes the immediate financing risk, but it also raises the bar for clinical delivery. The third-quarter interim results for OCU410ST will likely set the tone for the stock’s next leg — and determine whether the debt-fueled pipeline push was a calculated gamble or a bridge too far.